Cancer of the Uterine Cervix Clinical Trial
— DEPISTOfficial title:
Human Papillomavirus Testing Versus Liquid-based Cytology for Non-attendees of Cervical Cancer Screening: Results of a Randomised Controlled Trial
NCT number | NCT02698423 |
Other study ID # | CER 11-034 |
Secondary ID | |
Status | Completed |
Phase | N/A |
First received | |
Last updated | |
Start date | September 2011 |
Est. completion date | January 2016 |
Verified date | May 2018 |
Source | University Hospital, Geneva |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The purpose of this study is to determine whether human-papillomavirus (HPV) self-sampling can be used as a primary screening test for unscreened women.
Status | Completed |
Enrollment | 667 |
Est. completion date | January 2016 |
Est. primary completion date | January 2016 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Female |
Age group | 25 Years to 69 Years |
Eligibility |
Inclusion Criteria: - No previous cervical cancer screening test in the last three years Exclusion Criteria: - pregnancy - previous hysterectomy |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
University Hospital, Geneva |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Number of Participants Who Performed HPV Self-testing Compared to the Number of Participants Who Responded to the Invitation to Come to the Hospital for Pap Testing | Compare the participation rate to cervical cancer screening for home-based human papillomavirus testing based on self-sampling versus clinic-based, physician-performed Pap testing. | 1 year | |
Secondary | Proportion of Women With a Positive HPV Self-test Who Underwent All the Recommended Follow-up Clinical Investigations. | Assess the compliance with further follow-up among women having tested positive for the presence of HPV at baseline screening. | 1 year |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01663753 -
Diagnostic Performance of 18F-FDG-PET and Diffusion-weighted MRI in the Assessment of Stage IB to IIB2 Cervical Squamous-cell Carcinoma Response to Concomitant Radiochemotherapy and Brachytherapy
|
N/A | |
Not yet recruiting |
NCT05824494 -
Cadonilimab Plus Nab -Paclitaxel for Patients With Recurrent, or Metastatic Cervical Cancer Resistant to Immune Checkpoint Inhibitors
|
Phase 2 | |
Completed |
NCT00193934 -
Magnetic Resonance Imaging (MRI) Staging of Cervix Cancer
|
N/A | |
Completed |
NCT05384366 -
Neoadjuvant Chemotherapy in Cervical Cancer
|
Phase 3 |